Proposed legislation would subject e-cigarettes to age verification law
New legislation proposed June 5 by Congresswoman Rosa DeLauro, D-Conn., would require Internet and mail order sellers of electronic cigarettes to verify a person’s age and identity before they deliver their products to a buyer’s door.
Early Screening for Lung Cancer? Many people are not aware you can be tested for the disease
Lung cancer is the second most common cancer in both men and women, and is by far the leading cause of cancer death. In 2017, the American Cancer Society estimates more than 200,000 new cases of lung cancer will be diagnosed in the United States, with more than 150,000 deaths. Lung cancer screening is now approved in the United States, and can help detect cancer early, when it is most curable. With November Lung Cancer Awareness Month, Lynn Tanoue, MD and Polly Sather, MSN, APRN, from the Lung Screening and Nodule Program at Yale Cancer Center, talk about lung cancer screening and why it can save lives.
New research alliance with pharma giant
Yale School of Medicine and the pharmaceutical company AstraZeneca (AZ) have embarked on a new collaboration, supported by AZ’s Oncology Global Medical Affairs group, that aims to speed translational and clinical research to develop lifesaving, next-generation therapies for lung and other cancers.Source: Medicine@Yale
Precision Medicine: Custom Treatment From Your Genes
In 2001, we thought it was a remarkable accomplishment to sequence an entire human genome and do that once. Today, we're doing this thousands of times a day around the world. These lead to not just new diagnoses, but also can lead to new therapies that might not have been thought of previously.Source: WebMD
Yale Cancer Center receives $11 million from National Cancer Institute for lung cancer research
Armed with an $11 million grant from the National Cancer Institute (NCI), Yale Cancer Center and Smilow Cancer Hospital at Yale-New Haven will launch a new research program in non-small cell lung cancer, one of the world’s most prevalent and lethal forms of cancer.
How the Lung-MAP Clinical Trial is Responding to Rapidly Changing Science
When the Lung Master Protocol clinical trial (Lung-MAP or S1400) (1) was launched in June 2014, the goal of this first-of-its kind trial was simple: find effective treatments for seriously ill patients suffering from a specific type of lung cancer. Lung-MAP is unique—a biomarker driven, multi-drug, multi-arm, study design, using a targeted screening approach, with state-of-the-art genomic profiling of neoplastic cells to match patients with sub-studies testing investigational new drugs and immuSource: The Cancer Letter
We wanted to take an opportunity and communicate to you that our entire Yale PCCSM team have been awestruck by the courage and esprit de corps exhibited by so many of our YSM colleagues have joined forces with us to help care for the increasing numbers of critically ill COVID-19 patients in our units.
Meet Yale Internal Medicine: Vivian Asare, MD, Assistant Professor of Medicine (Pulmonary, Critical Care, and Sleep Medicine).
As part of our “Meet Yale Internal Medicine” series, today’s featured physician is Vivian Asare, MD, assistant professor of medicine (pulmonary, critical care, and sleep medicine).
With Cellular Blueprint for Lungs, Yale Researchers Look Ahead to Organ Regeneration
Using sophisticated screening across animal species, researchers at Yale have created a cellular blueprint of the human lung that will make it easier to understand the design principles behind lung function and disease — and to bioengineer new lungs. The research, published Dec. 4 in Science Advances, represents a collaboration between two Yale labs — that of Naftali Kaminski, M.D., chief of pulmonary, critical care, and sleep medicine at Yale School of Medicine, and Laura Niklason, M.D., Ph.D., the Nicholas Greene Professor of anesthesiology and biomedical engineering and an expert in stimulating growth of new lung tissue from the body’s own cells for use in transplants.
Yale Study Provides Insights Into How Fibrosis Progresses in the Human Lung
A Yale-led collaborative study boosts scientific understanding of how the lung disease idiopathic pulmonary fibrosis (IPF) progresses, providing a roadmap for researchers to discover new treatment targets for the disease.
Moving Toward Family-friendly Intensive Care Units
As with other forms of health care, there is increasing desire by patients and their loved ones to be more involved in what happens in hospital intensive care units (ICUs). But it is possible this desire can clash with pressures that are inherent in caring for patients whose health is so precarious, and ingrained routines that ICU staff often embrace. Yale clinicians, in a study published in Critical Care Medicine, collaborated with the Society of Critical Care Medicine (SCCM) to demonstrate potential routes for making intensive care more patient- and family-centered.